论文部分内容阅读
将１０６例急性心肌梗塞（ＡＭＩ）患者分为两组，≥７０岁组３１例，＜７０岁组７５例，均在发病６小时内接受尿激酶静脉溶栓治疗。结果：≥７０岁组与＜７０岁组比较，血管再通率分别为６７．７％及７０．６％（Ｐ＞０．０５），４周病死率分别为６．５％及５．３％（Ｐ＞０．０５），左室射血分数（ＬＶＥＦ）分别为０．４９±０．１２及０．５１±０．１４（Ｐ＞０．０５），出血并发症分别为４５．１％及２０％（Ｐ＜０．０１）。血管再通者与血管未通者比较，病死率分别为２．７％及１２．５％（Ｐ＜０．０５），ＬＶＥＦ分别为０．５６±０．１４及０．４４±０．１１（Ｐ＜０．０１）。因此认为，溶栓治疗ＡＭＩ的疗效与年龄无关，而与血管是否再通密切相关。老年ＡＭＩ患者行溶栓治疗虽出血等并发症高，但其利大于弊。
One hundred and sixty patients with acute myocardial infarction (AMI) were divided into two groups: 31 patients ≥70 years old and 75 patients <70 years old, all of whom received intravenous thrombolysis of urokinase within 6 hours after onset. Results: The rates of vascular recanalization were 67.7% and 70.6%, respectively, in the group of ≥70 years old and <70 years old. The 4-week mortality rates were 6.5% and 5.3% % (P> 0.05), left ventricular ejection fraction (LVEF) were 0.49 ± 0.12 and 0.51 ± 0.14 respectively (P> 0.05), bleeding complication was 45.1 % And 20% (P <0.01). The rates of mortality were 2.7% and 12.5%, respectively (P <0.05), and the LVEF were 0.56 ± 0.14 and 0.44 ± 0.11 (P <0.01). Therefore, the therapeutic effect of thrombolysis AMI has nothing to do with the age, and blood vessels are closely related again. Elderly patients with AMI thrombolytic therapy despite bleeding and other complications, but its benefits outweigh the disadvantages.